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The E3 ubiquitin ligase Siah regulates key cellular
events that are central to cancer development and
progression. A promising route to Siah inhibition is
disrupting its interactions with adaptor proteins.
However, typical of protein-protein interactions,
traditional unbiased approaches to ligand discovery
did not produce viable hits against this target,
despite considerable effort and a multitude of
approaches. Ultimately, a rational structure-based
design strategy was successful for the identification
of Siah inhibitors in which peptide binding drives
specific covalent bond formation with the target.
X-ray crystallography, mass spectrometry, and func-
tional data demonstrate that these peptide mimetics
are efficient covalent inhibitors of Siah and antag-
onize Siah-dependent regulation of Erk and Hif
signaling in the cell. The proposed strategy may
result useful as a general approach to the design of
peptide-based inhibitors of other protein-protein
interactions.
INTRODUCTION
Seven in Absentia (Sina) is a Drosophila protein that targets
Tramtrack, a transcription factor involved in fly eye development,
for degradation (Tang et al., 1997). Siah1 and 2 are the mamma-
lian orthologs of Sina, which are highly conserved across species
(Della et al., 1993). Siah1 and Siah2 are the products of separate
genes, which are activated by distinct mechanisms, yet are high-
ly homologous (85% identity) and target common substrates
(House et al., 2009). Siah is a RING finger E3 ubiquitin ligase
implicated in diverse biologic processes, such as p38/JNK/
NF-kB signaling pathways (Habelhah et al., 2002, 2004; Nadeau
et al., 2007; Nakayama et al., 2004; Zhang et al., 1998), DNA
damage (Winter et al., 2008), estrogen signaling (Frasor et al.,
2005), programmed cell death (Roperch et al., 1999; Xu
et al., 2006), Ras/Raf pathway (Nadeau et al., 2007; Schmidt
et al., 2007), mitosis (Bruzzoni-Giovanelli et al., 1999), and hyp-
oxia (Nakayama et al., 2004, 2009).
The crystal structure of Siah1 lacking the RING domain (Siah1-
DRING) revealed a dimeric organization (Figure 1A) that has been
linked with Siah activity (Santelli et al., 2005), including self- andChemistry & Biology 20, 97targeted ubiquitination and degradation (Ahmed et al., 2008;
Mo¨ller et al., 2009). Siah binds some of its substrates directly,
whereas others require adaptor proteins such as Siah-interact-
ing protein (SIP) (Matsuzawa and Reed, 2001) and phyllopod
(Boulton et al., 2000; Dong et al., 1999; Li et al., 1997; Tang
et al., 1997).
A number of Siah2 substrates, and the signaling pathways
regulated by them, including TRAF2 (JNK/p38/NF-kB) (Habelhah
et al., 2002), Sprouty2 (Raf/Ras signaling; Nadeau et al., 2007),
and PHD1/3 (hypoxia; Nakayama et al., 2004), have been impli-
cated in cancer development and progression (Fernandez-
Medarde and Santos, 2011; Semenza, 2010). Genetic inhibition
of Siah1/2 using RNA interference in tumor cell lines resulted in
suppression of the development of melanoma and prostate,
pancreatic, mammary, and lung tumors (Ahmed et al., 2008;
Bedogni and Powell, 2009; Davies et al., 2002; Mo¨ller et al.,
2009; Nakayama et al., 2009; Qi et al., 2008, 2010a; Schmidt
et al., 2007; Shah et al., 2009). Accordingly, Siah2 expression
and activity are upregulated in these tumors in both xenografts
and genetic mouse models (Ahmed et al., 2008; Confalonieri
et al., 2009; Scortegagna et al., 2011). In addition, it has been re-
ported that Siah directly interacts and ubiquitylates synphilin-1
and that Siah is present in Lewy bodies, presumably providing
a link to its possible role in Parkinson disease (Avraham et al.,
2005; Liani et al., 2004; Nagano et al., 2003; Szargel et al.,
2009). Collectively, these observations suggest that Siah inhibi-
tors could have significant therapeutic value.
In recent years, the search for an inhibitor of Siah has focused
on the adaptor Drosophila protein phyllopod. Mo¨ller and col-
leagues discovered that Siah inhibitory properties resided in the
first 130 amino acids of Drosophila phyllopod (PHYL 1–130).
Overexpression of PHYL 1–130 inhibits Siah-induced substrate
degradation (Mo¨ller et al., 2009), breast cancer progression (Mo¨l-
ler et al., 2009), and reduces melanoma metastasis (Qi et al.,
2008) and prostate tumor development and metastasis (Qi
et al., 2010a). Subsequently, House and colleagues identified
a 23-residue peptide derived from the Drosophila phyllopod
protein (Table 1) that binds with low micromolar affinity to the
substrate-binding domain of Siah (House et al., 2003, 2006). A
cell-penetrating version of PHYL 108–130 inhibits Siah ubiquitin
ligase activity in cell culture (Mo¨ller et al., 2009). Therefore, inde-
pendent lines of evidence suggest that PHYL-related sequences
couldprovide thebasis for development of therapeutics targeting
Siah (House et al., 2003, 2006;Mo¨ller et al., 2009;Qi et al., 2010b).
In principle, this peptide provides an excellent tool for the
development of a high throughput screening (HTS) campaign3–982, August 22, 2013 ª2013 Elsevier Ltd All rights reserved 973
Figure 1. X-Ray Structure of Siah1 in
Complex with BI-107E1
(A) Ribbon representation of Siah1-DRING in
complex with BI-107E1. The PHYL binding
domain is depicted in cyan, the two Zn-fingers in
yellow and blue, respectively. Zn ions (black) and
their coordinating residues (green stick models)
are displayed, while the side chain of Cys130 is
labeled and displayed in orange. BI-107E1 (red)
assumes an extended conformation and partici-
pates in a b sheet formation with Siah1.
(B) Detail of the binding mode of BI-107E1
(stick representation) on the surface of Siah1.
Aba118 indicates the ethyl-glycine residue at
position 118 of the peptide (Table 1). The
two hydrophobic P1 and P2 subpockets used
in our optimization strategies as well as the
location of Cys130 are schematically indicated.
BI-107E1 in its 2fo-fc electron density map
contoured at 1.2 s. The proximity of peptide
residue 118 and protein residue Thr156 are
highlighted.
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ever, typical of drug discovery campaigns that target protein-
protein interactions, these efforts did not result in any viable hits.
We previously reported the high-resolution (2.2 A˚) crystal
structure of Siah1 in complex with a peptide from Siah-interact-
ing protein (SIP), which contains the PXAXVXP consensus bind-
ing sequence also present in PHYL 108–130 (Santelli et al.,
2005). A low-resolution (3 A˚) structure of Siah1 in complex with
PHYL 108–130 was also reported (House et al., 2006), while
we report here the structure of Siah1 in complex with a smaller
PHYL-derived peptide (Figure 1A; Table 2). Because PHYL
108–130 binds in an identical mode as SIP, we used its sequence
as the starting point for developing high-affinity peptide-based
inhibitors.
As a result of several successful cases of effective therapeu-
tics, drugs that bind their target by means of covalent attach-
ment have recently come back into favor following initial fears
by the pharmaceutical industry about possible off-target effects
(Singh et al., 2011). In recent years, more emphasis has been
placed on combining the distinct strengths of covalent and non-
covalent modes of drug action with the design of compounds
that carefully balance reactivity with specific target complemen-
tarities. With the notable exception of suicide protease inhibitors,
peptides have been largely underexplored in this regard, yet
make an excellent platform for the development of this class
of therapeutics. We report the rational development of potent,
selective, and irreversible peptide-based inhibitors against
Siah. We also show X-ray, mass spectroscopy, and functional
data for this class of molecules targeting Siah.
RESULTS AND DISCUSSION
Because the residues in Siah1 and Siah2 involved in phyllopod
binding are conserved, we used constructs of either isoform
interchangeably in the various binding and cellular assays. First,974 Chemistry & Biology 20, 973–982, August 22, 2013 ª2013 Elseviwe exploited the PHYL 108–130/Siah interaction for the develop-
ment of a robust and reproducible lanthanide-based heteroge-
neous displacement assay (dissociation-enhanced lanthanide
fluorescent immunoassay [DELFIA]) platform that could be
used in HTS campaigns aimed at identification of Siah inhibitors.
Initially we screened 16,009 compounds from an in-house com-
pound collection using the DELFIA assay. However, this screen
revealed no viable hits when tested at 50 mM. In addition, we
tested two large combinatorial libraries of peptides from the Tor-
rey Pines Institute for Molecular Studies (two positional scanning
libraries of hexa-peptides and deca-peptides). However, after
deconvolution of the mixtures, resynthesis, and assessing
dose-response relationship, no viable hits were identified. We
concluded that the rather large and shallow PHYL binding sur-
face of Siah1 is an unlikely fit for ‘‘drug-like’’ small molecule inhib-
itors. The non-drugability of the PHYL-binding pocket is further
demonstrated by a subsequent nuclear magnetic resonance
(NMR)-based fragment screen of a library of approximately 500
scaffolds. For this task, we obtained 13C-methionine-labeled-
Siah2 and used chemical shift changes in 13C and/or 1H using
either two-dimensional [13C, 1H] HSQC spectra or one-dimen-
sional 13C-filtered 1H NMR spectra in absence or presence of
test ligands. These spectra are sensitive to binding because of
the presence of residue Met 180 in the PHYL binding pocket.
Again, no viable fragment hits were found. Similarly, in a parallel
effort employing the phyllopod homolog plectin, a screen from
the SBMRI MLPCN center of the National Institutes of Health
compound library of approximately 300,000 compounds using
a rhodamine-plectin–based fluorescence polarization displace-
ment assay (FPA) and secondary time-resolved fluorescence
resonance energy transfer displacement assay (TR-FRET) as-
says also revealed no viable hits (see http://pubchem.ncbi.nlm.
nih.gov bioassays AIDs 1817, 1826, 2127, and 2141 for details).
Hence, we redirected our efforts into more rational design
of PHYL mimetics. We first sought to define the region of theer Ltd All rights reserved
Table 1. Peptide Sequences, Molecular Weights, and IC50 Values Relative to the Ability of Each Molecule to Displace Biotin-PHYL in a
DELFIA against Wild-Type or Mutant T156C Siah
ID Sequence Molecular Weight
Wild-Type T156C
DELFIA IC50 (mM) DELFIA IC50 (mM)
PHYL Ac-108QQERTKLRPVAMVRPTVRVQPQL130-NH2 2,772 0.5 ND
BI-107D1 Ac-KLRPVAMVRPTVR-NH2 1,564 1 1
BI-107E12 Ac-KLRPVAMVRPMVR-NH2 1,594 1.3 0.9
BI-107F1 Ac-KLRPVAMVRPWVR-NH2 1,649 0.6 0.4
BI-107E1 Ac-KLRPVεMVRPTVR-NH2 1,664 2 2
BI-117C3 Ac-KLRPVdMVRPWVR-NH2 1,761 >100 0.006
BI-107F7 Ac-KLRPVAMVRPaVR-NH2 1,548 0.1 ND
BI-107F11 Ac-KLRPVAMVRPbVR-NH2 1,632 0.05 ND
BI-120G4 Ac-KLRPVdMVRPbVR-NH2 1,677 >100 0.001
PEN-P10 Ac-RQIKIWFQNRRMKWKKPPPPPPPPPP-NH2 3,259 ND ND
PEN-P10-PHYL Ac-RQIKIWFQNRRMKWKKPPPPPPPPPP 5,972 1.0 ND
QQERTKLRPVAMVRPTVRVQPQL-NH2
BI-107G3 Ac-RQIKIWFQNRRMKWKKPPPPPPPPPP 4,831 0.05 ND
KLRPVAMVRPbVR-NH2
BI-107F9 Ac-GRKKRRQRRRPQKLRPVAMVRPaVR-NH2 3,250 0.1 ND
BI-107F8 Ac-GRKKRRQRRRPQPMRAaPRVTVRLK-NH2 3,250 >100 ND
BI-107F10 (HIV-TAT) Ac-GRKKRRQRRRPQ-NH2 1,663 >100 ND
See also Table S1 for additional peptides synthesized and tested in the same assays and Figures S1 and S2 with chemical structures and synthetic
schemes. Cell-penetrating sequences are reported in italics. ε, Ethylglycine; d, DAP-acrylamide; a, Lys-acrylamide; b, Orn-acrylamide; Ac, acetyl; ND,
not determined.
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for binding to Siah1. Using the DELFIA assay we identified the
13-mer, KLRPVAMVRPTVR (BI-107D1; Table 1) as a suitable
starting point for optimization, given that it retained similar
displacement activity of the longer peptide. The BI-107D1
sequence comprises the residues that form close contacts
with Siah in the crystal structures of Siah-peptide complexes
(House et al., 2006; Santelli et al., 2005). However, initial
attempts to derive mimetics of BI-107D1 with improved affinity
for Siah were unsuccessful (Table S1 available online).
Noticeable in the Siah1 crystal structures (House et al., 2006;
Santelli et al., 2005) is the existence of two small hydrophobic
pockets, one adjacent to the site of binding of the methyl side
chain of PHYL residue Ala118 (P1 in Figure 1B) and the other cor-
responding to the binding site adjacent to PHYL residue Thr123
(P2 in Figure 1B). In an attempt to exploit these subpockets and
to improve potency of the peptide, we introduced different amino
acids at these positions with a variety of side chain lengths and
geometry (Table 1; Table S1). Of the peptides produced in our
initial studies, only BI-107E1 (half-maximal inhibitory concentra-
tion [IC50] = 2 mM; Table 1), an ethyl-glycine substitution at posi-
tion 118, efficiently competed for binding with the reference
PHYL peptide. To better understand the binding mode of this
peptide, we determined the crystal structure of BI-107E1 bound
to Siah1 at 3 A˚ resolution. The structure demonstrated that the
extra methyl group was accommodated without significant
changes in the peptide binding mode or distortions in the protein
(Figure 1B).
Similarly, substitution of Thr123 with more hydrophobic resi-
dues that reached farther into the P2 pocket resulted in peptides
with modestly increased affinities (BI-107E12 and BI-107F1,Chemistry & Biology 20, 97Table 1). Despite this limited success, further simple amino
acid replacements resulted in peptide mimetics with dramati-
cally reduced binding affinities for Siah (Table S1) and thus
making this simple route not a viable strategy for improvement;
this result is not entirely surprising given the already optimal
fit between the PHYL peptide and the shallow binding pocket
on Siah.
Recent efforts aimed at improving the binding affinity of small
molecule drugs for their receptor involve the introduction of a
mildly reactive group (usually a Michael acceptor such as an
acrylamide) designed to react selectively with a cysteine thiol
group present in the target binding site. This approach, originally
proposed by Shokat and colleagues to obtain selective inhibitors
of kinases (Maly et al., 2004), is currently exploited in several
inhibitor optimization efforts when a cysteine residue is proximal
to the binding site and has led to advanced and orally active clin-
ical candidates (Singh et al., 2011). In an attempt to derive more
potent and selective Siah inhibitors, we applied this approach to
BI-107F1. An initial proof-of-concept approach consisted in
replacing the side chain of BI-107F1 Ala118 with a suitably reac-
tive ‘‘warhead’’ that could form a covalent bond with a cysteine
residue present in the P1 pocket of Siah (Figure 2A). Although
wild-type Siah contains no such cysteine at this position, simple
modeling suggested that by mutating Siah Thr156 to cysteine
and adding the warhead, Dap-acrylamide (Dap-acm), in lieu of
Ala118, binding of the resulting BI-117C3 (Table 1; Figure 2A)
compound in its standard configuration would bring the acryl-
amide into apposition with the cysteine sulfhydryl group. Nucle-
ophilic attack by the cysteine sulfur on the acrylamide alkene
bond (Michael addition) could then ensue and result in the forma-
tion of a covalent thioether bond between Siah and the peptide.3–982, August 22, 2013 ª2013 Elsevier Ltd All rights reserved 975
Table 2. Data Collection and Refinement Statistics
BI-107E1 BI-107F7 BI-117C3
Data Collection
Space group P21 I23 I23
Cell parameters
a, b, c (A˚) 39.82, 87.94,
59.90
160.98 164.23
a, b, g () 90, 100.6, 90
Resolution (A˚) 50–3.0
(3.11–3.00)
120–2.4
(2.44–2.40)
30–2.8
(2.95–2.80)
Rmerge 0.077 (0.60) 0.073 (0.662) 0.123 (1.673)
I/sI 25.1 (2.5) 22.2 (2.2) 12.1 (1.5)
Completeness (%) 99.5 (97.7) 99.8 (99.8) 100.0 (100.0)
Redundancy 3.7 (3.7) 5.1 (5.1) 11.4 (11.4)
Refinement
Resolution (A˚) 40–2.9
(3.08–3.0)
30–2.4
(2.46–2.40)
30–2.8
(2.87–2.80)
No. reflections 7,751 25,786 17,329
s cutoff none none none
Rwork/Rfree 0.186/0.260
(0.288/0.437)
0.171/0.202
(0.257/0/331)
0.180/0.21.9
(0.356/0.444)
No. atoms
Protein 3,123 3,186 3,265
Ligand/ion 4 4 4
Solvent 14 152 7
Average B-factors
Protein 101.8 60.3 85.6
Ligand/ion 107.6 57.9 87.5
Water 67.9 65.0 68.9
Rmsd
Bond lengths (A˚) 0.005 0.005 0.007
Bond angles () 0.91 1.03 1.16
Values in parentheses are for highest-resolution shell. Rmsd, root-mean-
square deviation.
Figure 2. Structural Characterization of Siah1-T156C in Complex
with BI-117C3
(A) Schematic representation of the peptide-Siah covalent complex.
(B) View of BI-117C3 (stick representation) bound to Siah-T156C (surface).
Although two alternative conformations were modeled for Dap-acrylamide at
position 118 and Trp123 of the peptide and for Siah1 Cys156 in the Siah1/
BI-117C3 complex, only one is shown here for clarity. See also Figures S1 and
S2 regarding the chemical structure of BI-117C3 and its synthesis.
(C) Close-up view of the covalent bonds formed between BI-117C3 and Siah1
T156C shown in its 2fo-fc electron density maps contoured at 1.2 s. The bond
is marked with an asterisk. Dap118 indicates the Dap-acrylamide residue
introduced at position 118 of the peptide (Table 1). Only the electron density
around residues close to the reacting groups is shown.
(D) MALDI-TOF MS spectra of Siah1 in the presence of BI-117C3. The spectra
of wt-Siah1 in absence and presence of 117C3 are reported on the right, while
the spectra of Siah1-T156C in the absence and presence of the same peptide
are reported on the left. Note that the molecular weight of Siah1-T156C (left) is
larger than that of wt-Siah1 (right) because the latter lacks the 6His-tag.
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130 from the T156C Siah1 mutant, but not from wild-type Siah1,
with an IC50 value of 0.006 mM (Table 1). Of note is that IC50
values of covalent inhibitors are obviously relative to the assay
conditions and incubation times. Hence, the reported IC50 values
for these covalent compounds refer to our standard DELFIA pro-
tocol (see Experimental Procedures) and therefore serve only as
a way of rank-ordering the relative potency of the compounds.
We next solved the crystal structure of BI-117C3 / T156C
Siah1 complex at 2.8 A˚ resolution (Table 2). The map reveals
continuous electron density that is fully consistent with a cova-
lent thioether bond linking the modified peptide to Cys156 (Fig-
ures 2B and 2C). The bond is formed with 100% efficiency,
as judged by refined atomic B-factors. Moreover, the core
PV(Dap-acm)MVRP motif is bound to Siah in its standard orien-
tation without significant distortion of the substrate-binding
domain or the disposition of the second zinc finger domain while
the newly introduced tryptophan occupies the P2 pocket
(Figures 2B and 2C). To confirm the covalent modification of
Siah1, we used MALDI-TOF mass spectrometry, which demon-976 Chemistry & Biology 20, 973–982, August 22, 2013 ª2013 Elsevistrated the expected mass increase when BI-117C3 was incu-
bated with Siah1 T156C (Figure 2D) within the experimental
error. As expected, BI-117C3 was unable to covalently modify
wild-type Siah1 (Figure 2D). Because Siah possesses additional
solvent exposed Cys residues, these data further confirm that
the mildly reactive functionality introduced in the peptide reacts
only with the directed Cys residue, after proper binding takes
places.
We next sought a solvent-accessible cysteine residue in the
wild-type protein adjacent to the peptide-binding site to exploit
in this manner. We observed that the side chain of Cys130,er Ltd All rights reserved
Figure 3. Structural Characterization of Wild-Type Siah1 in Complex
with BI-107F7
(A) Schematic representation of the peptide-Siah covalent complex.
(B) View of BI-107F7 (stick representation) bound to wt-Siah (surface),
reported in the same orientation as in Figure 2.
(C) Close-up view of the covalent bonds formed between BI-107F7 and
wt-Siah1 shown in its 2fo-fc electron density maps contoured at 1.2 s. The
bond is marked with the asterisk. Lys-acr refers to the Lysine-acrylamide
residue introduced at position 123 of the peptide (Table 1). Only the electron
density around residues close to the reacting groups is shown.
(D) MALDI-TOF MS spectra of wt-Siah1 collected in absence and presence of
BI-107F7 and BI-107F11, respectively.
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pocket (Figure 1 and Figure 3A). Cys130 is adjacent to, but not
part of, the Zn2+-binding motif of the second zinc finger domain
(Figure 1). Using modeling techniques, we predicted that
replacement of BI-107F1 at position 123 with a lysine residue
with the side chain amino group conjugated to an acrylamide
group (Lys-acm, BI-107F7; Table 1) should provide a warhead
of suitable length to enable thioether bond formation between
wild-type Siah and BI-107F7 without disturbing other (noncova-
lent) interactions. Indeed, we found that BI-107F7 efficiently
competed with PHYL 108–130 for binding to Siah1 (IC50 =
0.1 mM; Table 1).
The Siah1/BI-107F7 complex was determined at 2.4 A˚ resolu-
tion (Table 2). We observed continuous electron density between
the peptide and Cys130 of Siah1 that was fully consistent with
the presence of the modified lysine side chain linked directlyChemistry & Biology 20, 97to the protein via a thioether bond (Figures 3B and 3C).
MALDI-TOF mass spectrometry confirmed the formation of the
covalent complex (Figure 3D).
Upon inspection of the Siah1/BI-107F7 crystal structure data,
it became apparent that a peptide with a side chain linker shorter
by one methylene group may allow for a more optimal distance
between the two reactive groups. Thus we introduced an
ornithine-acm at position 123 resulting in BI-107F11 (Table 1).
Indeed, BI-107F11 was about twice as effective as BI-107F7 at
competing for binding to Siah1 (IC50 = 0.05 mM; Table 1). A pep-
tide that combines the functionality of BI-117C3 and BI-107F11
was also synthesized and tested. BI-120G4 (IC50 = 0.001 mM;
Table 1), with both a Dap-acm in place of Ala118 and Orn-acm
in place of Thr123, was even more efficient at disrupting the
PHYL-SiahT156C interaction than BI-117C3 under the same
DELFIA experimental conditions.
BI-120G4 could be a useful chemical probe in the further
elucidation of the Siah mechanism of action in cells that stably
express Siah1 T156C. BI-107F11 and BI-107F7, although less
potent, could be used in cell-based assays targeting wild-
type Siah.
In the cell, Siah targets PHD1/3 for ubiquitination and degrada-
tion, thereby destabilizing HIF-1a (Nakayama et al., 2004).
Accordingly, Siah inhibition stabilizes PHD3. A cell-penetrating
version of PHYL 108–130 with an N-terminal penetratin-P10
sequence (Pen-P10; Table 1) has been previously reported to
antagonize Siah mediated PHD3 degradation (Mo¨ller et al.,
2009). Similarly, we fused the most promising covalent peptides
targeting Cys130 to either Pen-P10 for comparison with the pre-
viously reported peptide or with a simpler cell penetrating
sequence from HIV-TAT (Table 1). Adding Pen-P10 to the N ter-
minus of BI-107F11 resulted in BI-107G3 (Table 1). We found
that BI-107G3 more efficiently reduced the level of HIF-1a in
human melanoma Lu1205 cells that were maintained under hyp-
oxia than did Pen-P10-PHYL (Figure 4A). As expected, BI-107G3
also stabilizes PHD3 more efficiently than Pen-P10-PHYL in
HEK293T cells (Figure 4B). It should be noted that the cell-based
system makes use of a HA-Siah and Myc-PDH3 stable expres-
sion system. As a result, the levels of both enzyme and substrate
in these cells are higher than endogenous levels. This could have
a large inflationary effect on the half-maximal effective concen-
tration (EC50) values obtained with this assay even when testing
our covalent compounds. Notably, the dose-dependent shift in
HA-Siah migration (Figure 4B) may reflect covalent binding of
BI-107G3 to Siah in the cellular context. These findings establish
the ability of a BI-107G3, which covalently binds Siah, to atten-
uate Siah-mediated degradation of PHD3, with concomitant
effects on HIF-1a levels. Interestingly, BI-107G3 inhibition of
Siah also reduced Erk phosphorylation, suggesting an Siah
effect on Sprouty2 (Nadeau et al., 2007; Qi et al., 2008), a nega-
tive regulator of Ras/Raf signaling, was also attenuated. Thus we
conclude that BI-107G3 represents an efficient covalent inhibitor
of Siah cellular activity.
To further address the specificity of the peptides in inhibiting
Siah in vitro and in cell, we tested the HIV-TAT cell-penetrating
version of BI-107F7, namely BI-107F9 and its scrambled equiv-
alent BI-107F8 (Table 1). Similar to what was previously
observed for PHYL (Mo¨ller et al., 2009), BI-107F7 was not effec-
tive in inhibiting Siah auto-ubiquitination in vitro (Figure 5A).3–982, August 22, 2013 ª2013 Elsevier Ltd All rights reserved 977
Figure 4. BI-107G3 Is More Efficient at Stabilizing PHD3 than
Pen-P10-PHYL
(A) Cell-permeable synthetic PHYL peptide inhibits HIF-1a stabilization during
hypoxia. LU1205 cells were treated with increasing amounts of compound in
DMEM (no serum) for 2 hr under normoxia or hypoxia (2% oxygen in hypoxia
workstation). The varied compound concentrations are 1, 10, 25, and 50 mM.
Control peptides used are Pen-P10-PHYL and Pen-P10 alone (Table 1). Blots
were probed for endogenous HIF-1a and phospho-Erk. Even loading was
confirmed with a-tubulin antibodies.
(B) To compare the inhibitory effects of BI-107G3 with that of Pen-P10-PHYL
and Pen-P10 alone, HEK293T cells were transfected with Myc-PHD3 and
HA-Siah2 and then treated with 1, 10, 25, and 50 mM of the corresponding
peptide. Cells were lysed 24 hr later and analyzed with western blotting with
FMyc, PHD3, and HA antibodies. Even loading was confirmed with a-tubulin
antibodies.
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BI-107F9 were efficient at inhibiting Siah2-directed ubiquitina-
tion of substrate OGDH (Figure 5B). Similarly, in the cell, we
found that addition of BI-107F9 (but not the control scrambled
peptide BI-107F8) attenuated Siah2 degradation of exogenously
expressed PHD3 (Figure 5C). Finally, BI-107F9 effectively
reduced the level of HIF-1a in mouse melanoma SW1 cells that
were maintained under hypoxia (Figure 5D). These observations
further substantiate the selectivity of the observed effects of the
covalent peptides on the inhibition of the PHD3-HIF-1a axis and
therefore on the hypoxia response in several cell lines. These
findings establish the ability of the reported covalent Siah pep-
tides to inhibit Siah-mediated degradation of PHD3 and other
substrates.978 Chemistry & Biology 20, 973–982, August 22, 2013 ª2013 ElseviSIGNIFICANCE
In conclusion, we have used a structure-based approach to
derive covalent peptide-based inhibitors of Siah that are
potentially orders of magnitude more effective than parent
peptides. These molecules could serve as chemical probes
to further assess the role of Siah in tumorigenesis as well
as to validate this complex ubiquitin ligase as a target for
anticancer therapies. Moreover, our data suggest that the
introduction of a mildly reactive Michael-acceptor in pep-
tides of moderate affinity may represent a different route
for the optimization of these molecules into more effective
peptide-based therapeutics.
EXPERIMENTAL PROCEDURES
Chemistry
Fmoc-Dap(acryl amide)-OH was prepared and used as a building block for
the synthesis of desired peptide in solid phase synthesis. Fmoc-Dap-OH
was acrylated with acryl chloride in the presence of aqueous sodium carbon-
ate in 1,4-dioxane to give the desired building block in 90% purity (see Supple-
mentary Experimental Procedures; Figure S1). Similarly, Fmoc-Orn(acryl
amide)-OH and Fmoc-Lys(acryl amide)-OH were prepared. Alternatively,
some peptide containing acryl amides were synthesized using Dde as protect-
ing group on Dap, Orn, and Lys in their side chain, after completion of peptide
sequence on the resin, Dde group was selectively removed by the treatment of
2% hydrazine in DMF, followed by addition of acryl acid using standard pep-
tide coupling conditions. Resin and all other protecting groups were removed
using TFA. All final compounds were purified by high-performance liquid
chromatography using acetonitrile-water system. The detailed experimental
procedures for compounds synthesis, purification, and characterization are
provided as supplementary information (Figures S1 and S2).
Protein Expression and Purification
Siah1 81-282 and Siah1 81-282 (T156C) were subcloned into pET15b
(Novagen) and expressed as previously described (Santelli et al., 2005).
Siah1 81-282 (T156C) was constructed using QuikChange site-directed muta-
genesis (Stratagene) using Siah1 81-282 as a template.
DELFIA
One hundred microliters of a 100 ng/ml solution of biotin-PHYL (biotin-lc-
QQERTKLRPVAMVRPTVRVQPQL, where lc indicates a hydrocarbon chain
of 6 methylene groups) was added to each well of 96-well streptavidin-coated
plates (Perkin-Elmer). After 1 hr incubation and elimination of unbound biotin-
PHYL by three washing steps, 87 ml of Eu-labeled anti-his6 antibody solution
(300 ng/ml; 1.9 nM), 2.5 ml dimethyl sulfoxide solution containing test com-
pound, and 10 ml solution of his6-Siah1 (aa 81-282) or his6-Siah1 T156C
(aa 81-282) for a final protein concentration of 100 nM was added. After 1 hr
incubation at 0C, each well was washed five times to eliminate unbound pro-
tein and the Eu-antibody if displaced by a test compound. Subsequently,
200 ml of enhancement solution (Perkin-Elmer) was added to each well and
fluorescence measured after 10 min incubation (excitation wavelength,
340 nm; emission wavelength, 615 nm). Controls include unlabeled peptide
and blanks receiving no compounds. Protein and peptide solutions were
prepared in DELFIA buffer (Perkin-Elmer).
Mass Spectrometry Analysis
Molecular weight analysis was done using an Autoflex II MALDI TOF/TOF
(Bruker Daltonics). The reaction buffer (0.53 PBS) was used as a control to
compare against the spectra from protein incubated with peptide. For mass
spectroscopy analysis, equal volumes (2 ml) of each sample and MALDI
Matrix solution (sinapic acid; 20 mg/ml in 50% acetonitrile-0.1% trifluoroace-
tic acid solution) were cocrystallized on the MALDI target plate and allowed
to air dry for 5 min. Mass spectra were acquired and processed with
FlexAnalysis 2.4. The overlay protein molecular weight spectra against back-
ground buffer as well as control protein and peptide conjugated is shown. Theer Ltd All rights reserved
Figure 5. Effect of Siah2 Inhibitory Peptides on Siah2 Ubiquitination and Activity In Vitro and in Cells
(A) In vitro self-ubiquitination of Siah2 was performed in the presence of DMSO (control) or indicated concentrations of BI-107F7 (indicated as F7), with UB-HA
and ubiquitination reaction buffer. The degree of ubiquitination was monitored using antibodies to HA.
(B) In vitro ubiquitination of OGDH was monitored in the presence of indicated concentrations of BI-107F7 or BI-107F9 (indicated as F7 and F9, respectively).
Poly-ubiquitinated OGDH is marked on the right panel.
(C) BI-107F9 and BI-107F8 peptides were added to SW1 melanoma cells grown in culture, and the effect of Siah2 on exogenously expressed PHD3 was
monitored. Alpha-tubulin was monitored as a loading control.
(D) BI-107F9 and BI-107F10, at the indicated concentrations, were added to cultured melanoma cells maintained in 1% O2. Six hours later, cells were harvested
and the levels of HIF-1a and a-tubulin were assessed.
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conjugated sample. The data were further processed using the FlexAnalysis
peak picking method (using the Centroid mass find routine, with a signal-
to-noise threshold of 5, maximum number of peaks set to 50, a peak width
of 40 m/z, and height at 80% as well as Top Hat baseline subtraction). The
data reveal that under these conditions, a mass difference between replicates
is about 70 Da (as in Figure 3) or lower (as in Figure 2); these small deviations
are within Bruker Daltonics Manufacturer standards for a protein of 23 kDa. A
mass shift corresponding to Na+ and Ca+ is also observed additional to the
mass of the peptides.
X-Ray Crystallography
Siah1 81–282 (wild-type and T156C mutant) for crystallographic studies was
purified as described (Santelli et al., 2005). To crystallize the Siah1/E1 com-
plex by the sitting drop vapor diffusion method, Siah1 at 6 mg/ml was mixed
with a 2.5-fold excess of BI-107E1 and mixed with an equal amount of reser-
voir solution made of 10% polyethyleneglycol (PEG) 6000, 5% 2-methyl-2,4-
pentanediol (MPD), 100 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (HEPES) at pH 6.5. Twenty percent glycerol with 10% MPD was used
as cryoprotectant for data collection at beamline 9-2 at Stanford SynchrotronChemistry & Biology 20, 97Radiation Lightsource (SSRL). Data were reduced using HKL2000 (Minor
et al., 2000; (Table 2). The structure was solved by molecular replacement
with the program Phaser (McCoy et al., 2007) using residues 161–282 of
chain A of the Siah1-SIP complex (Santelli et al., 2005; Protein Data Bank
ID code 2a25) followed by manual fitting of the Zinc-finger domains and
the peptide, model building in Coot (Emsley and Cowtan, 2004), and refine-
ment with Refmac5 (Murshudov et al., 1997) without imposing noncrystallo-
graphic symmetry (ncs) constraints. The asymmetric unit (ASU) contains one
Siah1 dimer and one copy of BI-107E1 per Siah1 subunit. Refinement param-
eters are reported in Table 2. The complex between Siah1 and BI-107F7 was
obtained by mixing the protein with a 2-fold excess peptide and incubating at
4C for 16–18 hr. Thanks to the net positive charge on the peptide, the
Siah2F72 species was separated from Siah12F7 and Siah12 by anion ex-
change. Virtually all of the peptide in the recovered complex was covalently
bound to the protein as judged by SDS PAGE. Crystals were obtained by the
sitting drop vapor diffusion method using 60%–65% MPD and 100 mM
N,N-Bis(2-hydroxyethyl)glycine pH 9.0 as the reservoir solution. Data were
collected at SSRL beamline 12-2 and reduced with HKL2000 (Minor et al.,
2000). The structure was solved by molecular replacement and refined as3–982, August 22, 2013 ª2013 Elsevier Ltd All rights reserved 979
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peptide to Cys130 was visible from the early stages of refinement. The
ASU contains one Siah1 dimer (residues 92–282) and all 13 amino acids of
each copy of BI-107F7, 118 water molecules, and one MPD molecule. The
[Siah1(T156C)]2C32 complex was purified and crystallized as described for
Siah2F72, and a data set was collected at SSRL beamline 9-2 and reduced
with imosflm (Leslie and Powell, 2007). A refined Siah2F72 dimer was used
as a search model for molecular replacement. The final model contains
one Siah1 dimer covalently bound to two peptide molecules. All three refined
models with BI-107E1, BI-107F7, and BI-117C3 contain no residues in outlier
regions of the Ramachandran plot as assessed with rampage (Lovell et al.,
2002) with 97.9%, 98.4%, and 97.2% of residues, respectively, in the most
favored regions.
Cell Culture
Lu1205, SW1, and HEK293T cells were cultured in Dulbecco’s modified Ea-
gle’s medium (Thermo Scientific) supplemented with 10% fetal bovine serum
and antibiotics. Cell cultures were maintained at 37C in 5% CO2.
Plasmid and Transfection
The Flag-OGDH, HA-Siah2, Myc-PHD3, and GST-Siah2 plasmids have been
described previously (Habelhah et al., 2004; Scortegagna et al., 2011). GST-
siah2 was expressed in Escherichia coli BL21 and purified using immobilized
glutathione-Sepharose beads (Thermo Scientific) as described previously (Ha-
belhah et al., 2004). HEK293T cells were transfected using the jetPRIME DNA
transfection reagent kit (Polyplus, France) according to the manufacturer’s
protocol. In all cases, the total amount of DNA was normalized by the addition
of empty control plasmids.
In Vitro Ubiquitination Assay
Flag-OGDH protein was obtained from HEK293T cells transfected with FLAG-
OGDH. After transfection for 24 hr, cells are harvested and lysed in IP buffer
containing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton-X, 1 mM EDTA,
1 mM PMSF, 10 mg/ml aprotinin, 10 mg/ml leupeptin, and 1 mg/ml pepstatin A
for 30 min at 4C. After centrifugation at 13,000 3 g for 30 min at 4C, cell
lysate (1 mg protein) was incubated with 1 mg of mouse anti-Flag antibody
(Sigma) for 2 hr and further incubated for 2 hr with 20 ml of protein A/G
PLUS-agarose beads (Santa Cruz). The beads were washed three times
with the same lysis buffer and one time with ubiquitination assay buffer
(50 mM Tris-HCl, pH 8.0, 5 mM MgCl2, 0.5 mM dithiothreitol, 2 mM NaF,
and 2 mM ATP). Immunoprecipitated Flag-OGDH was subjected to an
in vitro ubiquitination assay (20 ml) in ubiquitination buffer supplemented
with purified GST-Siah2 (1 mg), HA-Ub (1 mg), E1 (UBE1, 50 mg), E2 (UbcH5c,
250 ng; HA-Ub, E1, and E2 are from Boston Biochem, Cambridge, MA), and
different amounts of Siah peptide inhibitors for 45 min at 37C. The reaction
mixtures were washed four times before being eluted in Laemmli buffer and
separated on 8% SDS-PAGE followed by western blot analysis with anti-
Flag antibody. The same ubiquitination reactions were performed to deter-
mine the effect of Siah peptide inhibitors on Siah self-ubiquitination in the
absence of Flag-OGDH in the reaction mixtures. After 45 min at 37C, the
reaction mixtures were mixed with Laemmli buffer, heated, and subjected
to 8% SDS-PAGE directly followed by western blot analysis with anti-HA
antibody. The same membrane was striped and reprobed with anti-GST
antibody.
Protein Preparation and Western Blotting
HEK293T cells were transfected with Flag-OGDH or Myc-PHD3, with or
without HA-Siah2, for 16 hr. Different amounts of different Siah peptide inhib-
itors were added to the cells and further incubated for 6 hr. Cells were then
washed with cold PBS and lysed in lysis buffer (50 mM Tris-HCl, pH 7.4,
150 mM NaCl, 1% NP-40, 1 mM EDTA, 10 mg/ml aprotinin, 1 mg/ml pepstatin
A, 10 mg/ml leupeptin, 2 mM phenylmethylsulfonyl fluoride, 20 mM microcys-
tin-LR, and 2.5 mM sodium orthovanadate) for 30 min on ice. Cell lysates
were obtained by centrifugation at 13,000 3 g for 30 min at 4C. The protein
concentration was determined using Bio-Rad protein assay solution. Equal
amounts of cell lysate (50 mg) were resolved by SDS-PAGE and transferred
to polyvinylidene difluoride membranes (PerkinElmer Life Sciences, Waltham,
MA). Membranes were blocked with 5% BSA/PBST for 1 hr and incubated980 Chemistry & Biology 20, 973–982, August 22, 2013 ª2013 Elseviwith primary antibodies (mouse anti-Flag antibody, Sigma, 1:1,000; mouse
anti-Myc antibody, Santa Cruz, 1:1,000; rabbit anti-HA antibody, Santa
Cruz, 1:1,000; mouse antitubulin antibody, Santa Cruz, 1:1,000) for 1 hr at
room temperature or overnight at 4C with shaking. Following a three-time
wash with PBST (PBS containing Tween 20, 0.05% v/v), membranes were
incubated with second antibody for 1 hr at room temperature. Bound anti-
bodies were detected with horseradish peroxidase-conjugated antirabbit
antibody (Cell Signaling) for polyclonal antibodies or horseradish peroxi-
dase-conjugated antimouse antibody (Cell Signaling) for monoclonal anti-
bodies followed by enhanced chemiluminescence using Western Lightning
reagent (Perkin-Elmer Life Sciences).
Hypoxia Treatment
Five hundred thousand Lu1205 cells were plated in a six-well plate and
allowed to attach overnight. Different amounts of different penetrating Siah
peptide inhibitors were added to the cells. Cells were exposed to hypoxia
(1%) for 6 hr and lysed immediately on ice as described previously. Cell
lysates were subjected to western blot analysis as described previously
with rabbit anti-HIF-1a antibody (a gift from Dr. Gary Chiang, 1:1,000). The
same membrane was striped and probed again with mouse antitubulin
antibody.
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The complex of Siah1DRING in complex with various covalent compounds
have been deposited in the Protein Data Bank under ID codes 4I7B, 4I7C,
and 4I7D.
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